Long-term study of eteplirsen, golodirsen, or casimersen for DMD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study follows people with Duchenne muscular dystrophy (DMD) who are taking eteplirsen, golodirsen, or casimersen. It aims to understand how these medicines work in everyday life over a long period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Duchenne muscular dystrophy (DMD), confirmed by a genetic test.
- You are currently taking eteplirsen, golodirsen, or casimersen, or plan to start one of these within 6 months.
- You are not taking part in any other research study that tests a new DMD treatment.
- You agree to let the study team use your genetic test results.
- You are willing to follow study procedures and provide information over time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a one-time gene therapy given by injection into the spinal fluid (intrathecal) for boys with Duchenne muscular dystrophy. It aims to see if the treatment is safe and how it spreads in the body, and may offer a new way to slow the disease.
This trial tests a new gene therapy called SGT-003 in boys and men with Duchenne muscular dystrophy who are still able to walk. The treatment aims to deliver a working version of the dystrophin gene to help muscle cells produce the protein they are missing.
This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.
This study follows people with Duchenne muscular dystrophy (a muscle-weakening condition) to track how the disease progresses over time. By collecting this data, researchers hope to better understand the condition and improve future care.
This study tests a new medication called KER-065 to see if it helps people with Duchenne Muscular Dystrophy (DMD). It may help boys and men who are still walking, as well as those who use a wheelchair, as long as they are on a stable corticosteroid treatment.
This trial tests a new drug (NS-089/NCNP-02) that aims to help boys with Duchenne muscular dystrophy produce a shorter but still working version of the dystrophin protein. It's for boys who are still walking and have a specific genetic type that can be fixed by skipping a part of the gene called exon 44.
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.